...By Jeff Cranmer, Executive Editor Shares of NexImmune Inc. (NASDAQ:NEXI) and Decibel Therapeutics Inc. (NASDAQ:DBTX) traded higher Friday...
...while immunotherapy play NexImmune raised $110 million through the sale of 6.5 million shares at $17. NexImmune...
...initial enterprise value of $3.9 billion with about $400 million in capital. Jeff Cranmer Forbion Capital Partners Decibel Therapeutics NexImmune Sagimet...

...of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune...
...Roads, General Atlantic, GP Healthcare Capital, Sequoia Capital China and Wuxi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359).NexImmune Inc.’s...
...cell-mediated immune responses.A syndicate led by former Celgene Corp. Chairman and CEO Sol Barer acquired NexImmune...

...manufacturing officer. McCubbin was head of technical operations at Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE).Immunotherapy play NexImmune Inc. hired Robert...
...officer; and separately appointed Grant Verstandig, chief digital officer at UnitedHealth Group Inc. (NYSE:UNH), to its board. Before NexImmune...
...Inc. T-knife GmbH Audentes Therapeutics Inc. Astellas Pharma Inc. Applied Molecular Transport Inc. Unity Biotechnology Inc. Frequency Therapeutics Inc. Cerevel Therapeutics Holdings Inc. NexImmune Inc. UnitedHealth...

...NASDAQ:NXTC) hired Han Myint as chief medical officer. Before joining NextCure, Myint was CMO of immunotherapy company NexImmune Inc....

...hematopoietic stem cell (HSC) transplant. AIM ACT is a CD8 T cell-activating therapy based on NexImmune’s...
...dysfunctional or absent natural antigen-presenting cells with artificial antigen-presenting cells that direct specific immune responses. NexImmune...
...see BioCentury, Feb. 17, 2017 ). NexImmune Inc., Gaithersburg, Md. Elizabeth S. Eaton AIM ACT Celgene Corp. Johns Hopkins University Medtronic plc NexImmune Inc. CD8...

...hematopoietic stem cell (HSC) transplant. AIM ACT is a CD8 T cell-activating therapy based on NexImmune’s...
...dysfunctional or absent natural antigen-presenting cells with artificial antigen-presenting cells that direct specific immune responses. NexImmune...
...CEO Sol Barer, his son Joshua, and former Medtronic plc (NYSE:MDT) CEO William Hawkins acquired NexImmune...

...about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc....
...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). On Feb. 14, the new syndicate acquired all NexImmune...
...Investments for an undisclosed sum. The new investor group also put additional undisclosed capital in NexImmune...

...An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer...
...who was chairman and CEO of Medtronic plc (NYSE:MDT, Dublin, Ireland); and other undisclosed investors NexImmune...
...the investment but are no longer represented. NexImmune Inc. , Gaithersburg, Md. Business: Cancer Jaime De Leon AIM ACT NexImmune Inc....

...including former CEOs of Celgene Corp. (NASDAQ:CELG) and Medtronic plc (NYSE:MDT) has acquired immuno-oncology company NexImmune Inc....
...undisclosed investors. Sol Barer became Teva's chairman last week (see BioCentury Extra, Feb. 6) . NexImmune...
...treat hematological malignancies. The candidate is a CD8 T cell-activating adoptive cellular therapy based on NexImmune’s...